The Cancer News Daily
The latest in cancer medicine and translational research by Wafik El-Deiry MDPhD
Related Articles
Synthetic anti-RNA antibody derivatives for RNA visualization in mammalian cells
Abstract. Although antibody derivatives, such as Fabs and scFvs, have revolutionized the cellular imaging, quantification and tracking of proteins, analogo
Mitochondrial fatty acid oxidation drives senescence
Nuclear DNA damage activates fatty acid–fueled mitochondrial energy metabolism to induce cellular senescence, a hallmark of aging.
Archived Issues of Oncotarget | Oncotarget
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal that has been publishing research since 2010
Mitochondrial fatty acid oxidation drives senescence
Nuclear DNA damage activates fatty acid–fueled mitochondrial energy metabolism to induce cellular senescence, a hallmark of aging.
‘Would he have lived?’ When insurance companies deny cancer care to patients
Health insurers are increasingly interfering in care, an NBC News investigation found. Doctors say the stakes are highest in cancer care, when delays can be…
Steward Health a cautionary tale in private equity’s push into health care
An investigation into Steward Health Care reveals a cautionary tale about the role of private equity in American health care and the corporate push for…
Lunatic accused of shoving commuter into path of NYC subway charged…
Kamel Hawkins was charged with attempted murder. The lunatic accused of randomly shoving a Big Apple straphanger onto Manhattan subway tracks Tuesday afternoon was charged…
Man pushed in front of New York City subway train injured but alive, police say
The incident occurred in the heart of Manhattan and a man has been taken into custody, but charges are yet to be filed
Pitfalls of FDA-approved germline cancer predisposition tests
BUFFALO, NY – December 30, 2024 – A new editorial was published in Oncotarget’s Volume 15 on December 24, 2024, titled “Pitfalls and perils from FDA-approved germ-line cancer predisposition…
Potential dangers of direct-to-consumer genetic test for cancer risk
A new editorial was published in Oncotarget’s Volume 15 on December 24, 2024, titled “Pitfalls and perils from FDA-approved germ-line cancer predisposition tests.”